Bayer suffered defeat at the hands of the EU General Court today, with the rejection of its attempt to register what the court deemed to be heart-related trademark.
Israel-based Teva has predicted 2019 will be a tough year, with lower revenue and profit, as the company faces generic competition for two of its top-selling drugs.
The Canadian units of IBM and pharmaceutical company Boehringer Ingelheim have united to explore the use of blockchain technology in clinical trials.
Swiss pharmaceutical company Roche Diagnostics has agreed to pay $21 million as part of a settlement to a patent infringement case with New York-based Enzo Biochem.
The lobby group for India’s pharma industry has asked the US Trade Representative office to remove India from its Priority Watch List of places that have weak enforcement of intellectual property laws.
UK patients could be more exposed to counterfeit medicines than EU patients in the event of a ‘no deal’ Brexit, because access to an initiative aimed at protecting patients from fake drugs could be lost.
The US Court of Appeals for the Federal Circuit yesterday dismissed an appeal by Massachusetts-based biotech Momenta Pharmaceuticals in a case involving a rheumatoid arthritis drug.
A US jury has ordered pharmaceutical company Baxalta Inc. to pay $155 million to Bayer Healthcare following a patent infringement trial.
UK headquartered GSK has made another move in the oncology space, signing a potential €3.7 billion immunotherapy deal with Germany-based Merck KGaA.
Rivals of British pharmaceutical company Indivior will soon be able to sell generic versions of opioid addiction treatment Suboxone film following a ruling of the US Court of Appeals for the Federal Circuit.